OncoVeryx Cancer Screen
A blood-based screening test that reads the serum metabolite signatures linked to cancer.
This is a screening test, not a cancer diagnosis. Any concerning result must be followed up with a healthcare professional.
A qualitative in-vitro diagnostic test.
OncoVeryx is a qualitative in-vitro diagnostic test developed by PredOmix. It analyses a serum sample from a simple blood draw and reads the metabolite signatures linked to the presence of cancer, across all stages (I to IV) and including early-stage, asymptomatic cancers.
What the test analyses
Metabolites are small molecules produced as your body breaks down food, medicines and its own tissues, the chemistry of everyday metabolism. Patterns in these molecules shift with changes in biological activity. OncoVeryx profiles the specific serum-metabolite patterns that research associates with cancer biology, rather than DNA or imaging.
From a blood sample to a screening result.
Step 1
Serum sample
A serum sample is prepared from a simple peripheral blood draw.
Step 2
LC-HRMS profiling
Metabolites are profiled using liquid chromatography coupled to high-resolution mass spectrometry.
Step 3
Proprietary algorithmic analysis
A proprietary deep-learning algorithm analyses the metabolite profile to identify cancer-associated signatures.
Step 4
Signature detection
The analysis reports whether a cancer-associated metabolite signature is present or absent.
Step 5
Tissue-of-origin support
When a positive signature is detected, the software indicates likely tissue-of-origin possibilities to support follow-up.
Screening that starts with a simple blood draw.
Some cancers are only found later, usually through invasive procedures. A blood-based screen offers an earlier, gentler and quicker way to screen for a cancer signal, so invasive tests are only done when necessary.
The current picture
Often found later
- Many cancers have no routine screening test today.
- They are often found later, once symptoms appear.
- Investigating them can involve invasive procedures.
- The later a cancer is found, the lower the chance of remission.
Screening with OncoVeryx
One simple blood test
- Screening starts with one simple blood draw.
- An easy, minimally invasive first step.
- Focuses further tests on the people most likely to need them.
The later it is found, the lower the odds
Survival rates drop sharply as a cancer advances. That is why early detection matters so much.
5-year survival by stage at diagnosis, shown for colorectal (bowel) cancer as an example (source: Cancer Research UK). These are general population statistics, not OncoVeryx results. Survival varies by cancer type, individual factors and treatment.
Minutes to collect
The blood draw itself takes just a few minutes.
Fits a normal visit
No booking, prep or recovery time of a separate procedure.
Results in about 10 working days
Typically returned within around 10 working days of the lab receiving your sample. Timing can vary.
What this does and doesn’t mean: only the screening step is a simple blood draw. OncoVeryx does not replace diagnosis. If a signal is found, further evaluation is still needed, and this may include imaging, laboratory tests or a biopsy. It also does not replace mammograms, Pap smears, colonoscopy, PSA testing or any other screening your doctor recommends. Please continue those as advised.
What each result means.
Every result is interpreted by a healthcare professional in the context of your medical history, signs and symptoms.
Cancer-associated signal detected
This may indicate the presence of cancer. The result does not confirm cancer. Further clinical evaluation is required, and your healthcare professional will refer you for further tests to confirm whether cancer is present.
No cancer-associated signal detected
This does not rule out cancer. Continue routine screening and medical advice from your healthcare provider.
Invalid
A fresh sample may be required if sample quality or quantity is insufficient for reliable analysis.
What the test does not do
- Does not diagnose cancer by itself
- Does not replace existing screening
- Does not replace your doctor
- Does not rule out every cancer
- Does not detect all cancers
- Does not evaluate pre-cancerous lesions
Important limitations
- False positive results can occur
- False negative results can occur
- Results must be interpreted with your medical history, signs and symptoms
- Suitability should be determined through healthcare guidance
Screening is not diagnosis
OncoVeryx does not confirm cancer and does not rule out all cancers. False positive and false negative results can occur. Continue with routine cancer screening recommended by your healthcare provider.
Discuss OncoVeryx with our team.
Speak to OmniHealth Africa about suitability, doctor referrals and access to the test.